SCHEMBL17808902

SCHEMBL17808902

CC(C)c1cnc2c(O)c(-c3ccsc3)ccn2c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNE1 P24864 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM5B Q9UGL1 1/20 0.37
▸ FYN P06241 1/20 0.36
▸ GRIN2D O15399 1/20 0.36
▸ GRIN3B O60391 1/20 0.36
▸ GRIN1 Q05586 1/20 0.36
▸ GRIN2A Q12879 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ GRIN2C Q14957 1/20 0.36
▸ GRIN3A Q8TCU5 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ FLT1 P17948 1/20 0.35
▸ FLT4 P35916 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24344159 0.85 CCNE1 (0.38) CCNE1CDK2NPC1RAB9ASMN1; SMN2
SCHEMBL17808751 0.84 RPS6KA3 (0.37) NPC1RAB9ASMN1; SMN2KDM5BFYN
SCHEMBL17808756 0.80 PTGS1 (0.36) NPC1RAB9ASMN1; SMN2KDM5BKDM4E
SCHEMBL17808904 0.79 TOP2A (0.36) FYNMEN1ALDH1A1KMT2A
SCHEMBL17808725 0.78 BRD4 (0.41) KDM5BFYNFLT1KDR
SCHEMBL19365017 0.76 KDM5A (0.37) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL19361112 0.75 TP53 (0.39) NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL17808905 0.75 KDM5B (0.38) NPC1RAB9ASMN1; SMN2KDM5BKDM4E
SCHEMBL17802285 0.75 KDM5A (0.36) KDM4EALDH1A1
SCHEMBL10027232 0.75 KDM5A (0.36) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227292-B1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS ALTERITY THERAPEUTICS LTD (AU) 2022-03-09 — — EP disclosed
US-20210230159-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2021-07-29 — — US disclosed
US-11008319-B2 4H-pyrido[1,2-a]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2021-05-18 — — US disclosed
US-20200317670-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2020-10-08 — — US disclosed
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2020-08-11 — — US disclosed
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2019-11-21 — — US disclosed
US-10287285-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2019-05-14 — — US disclosed
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2017-09-21 — — US disclosed
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2017-09-21 — — US disclosed
WO-2016086261-A1 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2016-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738050-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO CCNE1 853/4885CDK2 35/4885NPC1 783/4885
US-20200317670-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO CCNE1 853/4885CDK2 35/4885NPC1 783/4885
US-10287285-B2 4H-pyrido[1,2-A]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO CCNE1 853/4885CDK2 35/4885NPC1 783/4885
US-11008319-B2 4H-pyrido[1,2-a]pyrimidin-4-one compounds PSEN2, PSEN1, PNPO CCNE1 853/4885CDK2 35/4885NPC1 783/4885
US-20190352301-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO CCNE1 853/4885CDK2 35/4885NPC1 783/4885
US-20210230159-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO CCNE1 853/4885CDK2 35/4885NPC1 783/4885
US-20170267676-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS PSEN2, PSEN1, PNPO CCNE1 853/4885CDK2 35/4885NPC1 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback